Clinical Pathways in Neuro-ophthalmology : An ... - E-Lib FK UWKS

More documents

Recommendations

Info

484 Clinical Pathways in Neuro-Ophthalmology, second edition Thyroid eye disease (cont.) systemic thyroid status, 350 therapeutic management, 350–352, 355 horizontal diplopia, 224–226, 226 lid retraction/lid lag, 424–425 vertical diplopia, 241 Thyroid ophthalmopathy, binocular transient visual loss, 182 Tilted optic disc, papilledema, differential diagnosis, 131, 131 Tonic pupil Adie’s tonic pupil syndrome clinical features, 441, 444 etiology, 441 neuroimaging studies, 441 therapeutic strategies, 444 anisocoria, 440–441, 442–443 isolated, differential diagnosis, 441, 442–443 syphilis serology testing, 444–445 Toxic optic neuropathy, clinical features, 914, 15–16 Transient diplopia, etiology, 217, 218 Transient visual loss (TVL) binocular TVL etiology, 179–183 evaluation, 167, 169–170, 183 etiology, 171–179, 177 monocular TVL duration of episodes, reading-evoked TVL, 171–179 gaze positions, 168, 168169, 171 patient history, 167 prolonged reading, 171 Transurethral prostatic resection (TURP) syndrome, binocular transient visual loss, 183 Traquair’s junctional scotoma, visual field defects, 193–194 Trauma. See Orbital trauma fourth nerve palsies (FNP), 287 Horner’s syndrome and, 449, 451 ptosis etiology, 415 sixth nerve palsy (SNP), evaluation protocols, 301 Traumatic optic neuropathy (TON) clinical features, 9, 119, 119 evaluation and treatment flow chart, 125 grading and classification, 120, 121 neuroimaging, 119–120 pathogenesis, 119, 120 therapeutic management strategies, 120–126, 125 corticosteroid therapy, 122–123 protocols and classification, 123, 123 surgical management, 124–126 Trigemino-oculomotor synkinesis, lid retraction/lid lag and, 423–424 Trochlear nerve. See also Fourth nerve palsies (FNP) localization, 284 Tropias, diplopia evaluation, 219 T2-weighted imaging, internuclear ophthalmoplegia (INO), 319 Upbeat nystagmus, clinical features and etiology, 386–389, 388 Uveitis-glaucoma-hyphema (UGH) syndrome, transient visual loss, 175, 177 Valsalva maneuver binocular symmetric jerk nystagmus, 391 gaze-evoked transient visual loss (TVL), 170–171 Vasculopathic fourth nerve palsies (FNP), evaluation protocols, 287 Vasculopathic sixth nerve palsy (SNP) evaluation protocols, 301–302 risk factors, 302 Vasospasm, transient visual loss, 175–176 Venereal Disease Research Laboratory (VDRL) test, papilledema, clinical evaluation, 135 Venous occlusive disease, pseudotumor cerebri syndrome, evaluation protocols, 144–145 Venous stasis retinopathy, transient visual loss, 174–179 Vertebrobasilar transient ischemic attacks, binocular transient visual loss, 182
evaluation protocol, 183 Vertical diplopia cranial nerve impairment, 237–238 etiology, 234, 235–236 examination protocol, 232–234 extraocular muscle disease, 238–240 mechanical misalignment processes, 240–245 monocular elevator paresis, 234, 236–237 neuromuscular junction diseases, 238 supranuclear processes, 234, 236–237 Vertical gaze impairment anatomy, 321 etiology, 322, 324–325 evaluation protocols, 323, 325–326, 326 lesion localization of palsies, 321–322, 322–323 Vertical jerk nystagmus, clinical features and etiology, 385–389 Vertical ocular myoclonus, stuporous/ comatose patients, 399 Vertical pendular nystagmus, etiology, 370 Vertigo, binocular symmetric jerk nystagmus, 390–391 Vistibular tone imbalance, nystagmus etiology, 367368 i368 Visual acuity optical disc edema with macular star (ODEMA), 64 pseudotumor cerebri syndrome, optic nerve sheath fenestration (ONSF) and, 150–155 traumatic optic neuropathy (TON), 121–122 Visual field defects bilateral defects, clinical features, 192, 193 binasal hemianospia, 196, 198 bitemporal hemianopsia, 194, 195–196, 196 evaluation protocols, 190 homonymous hemianopsia, 198 lateral geniculate body lesion, 199–200 normal neuroimaging, 205–207 optic radiation, 201–202 optic tract lesions, 198–199 Index 485 therapeutic management, 207 junctional defects, 192–194 monocular temporal cresent, 192 occipital lesions, 202–205 optic neuritis (ON), 35–36 optic neuropathy, 191–192 pseudotumor cerebri syndrome, 144 retinal lesions, 189, 191, 191 topographical diagnosis, 189, 190 unexplained defects, 207–208 unilateral defects, 189 Visual loss giant cell arteritis (GCA), clinical diagnosis, 95–96, 96–98, 98–99 monocular nystagmus, 370 transient visual loss (TVL) binocular TVL etiology, 179–183 evaluation, 167, 169–170, 183 etiology, 171–179, 177 monocular TVL, duration of episodes, 171–179 monocular TVL, gaze positions, 168, 168–169, 171 patient history, 167 prolonged reading, 171 Visually evoked potentials (VEPs), optic neuritis (ON), indications for, 47 Visual prognosis nonarteritic anterior ischemic optic neuropathy (NA-AION), 79 levodopa therapy, 82–83 optic nerve sheath fenestration, 83, 83–85 optic disc edema with macular (ODEMS), 67, 69 optic neuritis (ON), 49–50 Visual recovery giant cell arteritis (GCA), therapeutic protocols, 106–108 optic neuritis (ON), 49–50 traumatic optic neuropathy (TON) corticosteroid therapy, 122–123 natural history and progression, 120–122 Vitamin A, idiopathic pseudotumor cerebri etiology, 140–142, 141
Page 2 and 3:
This page intentionally left blank
Page 4 and 5:
Page 6 and 7:
Thieme New York 333 Seventh Avenue
Page 8 and 9:
To our wives, Hilary and Liz and to
Page 10 and 11:
Page 12 and 13:
x Preface We would again like to th
Page 14 and 15:
2 Clinical Pathways in Neuro-Ophtha
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
10 Clinical Pathways in Neuro-Ophth
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Table 1-12. Clinical Features of Ra
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
100 Clinical Pathways in Neuro-Opht
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
13 r Sixth Nerve Palsies What is th
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
Page 386 and 387:
Page 388 and 389:
Page 390 and 391:
Page 392 and 393:
Page 394 and 395:
Page 396 and 397:
Page 398 and 399:
Page 400 and 401:
Page 402 and 403:
Page 404 and 405:
Page 406 and 407:
Page 408 and 409:
Page 410 and 411:
Page 412 and 413:
Page 414 and 415:
Page 416 and 417:
Page 418 and 419:
Page 420 and 421:
Page 422 and 423:
Page 424 and 425:
Page 426 and 427:
Page 428 and 429:
Page 430 and 431:
Page 432 and 433:
Page 434 and 435:
Page 436 and 437:
Page 438 and 439:
Page 440 and 441:
Page 442 and 443:
Page 444 and 445:
Page 446 and 447: 434 Clinical Pathways in Neuro-Opht
Page 476 and 477: Index r Page numbers in italic indi
Page 498: 486 Clinical Pathways in Neuro-Opht
show all

Clinical Pathways in Neuro-ophthalmology : An ... - E-Lib FK UWKS

Create successful ePaper yourself

Delete template?

Save as template?